window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 6, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Central Nervous System

  • Central Nervous System,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    ABLi reports biomarker changes supporting disease-modifying potential of Parkinson’s drug

    ABLi Therapeutics has reported coordinated changes across 11 biomarkers linked [...]

    August 4, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    Vaximm reports encouraging VXM01 data in recurrent glioblastoma studies

    Vaximm AG has completed analysis of two clinical studies evaluating [...]

    August 3, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    ProMIS reports no ARIA-E in Phase 1b Alzheimer’s trial of PMN310

    ProMIS Neurosciences has reported six-month interim safety and biomarker data [...]

    July 29, 2026
  • Central Nervous System,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    CHMP recommends approval of NEZGLYAL for rare neurodegenerative disease

    The EMA’s CHMP has recommended approval of NEZGLYAL for boys [...]

    July 24, 2026
  • Central Nervous System,Research & Development

    Brain network dynamics may better explain psychiatric symptoms than diagnoses

    Rutgers researchers found that changes in brain network dynamics were [...]

    July 22, 2026
  • Central Nervous System,Digital & Data,Medical devices

    Natus expands AI-powered EEG analysis across Europe

    Natus has expanded access to its AI-powered EEG analysis tool [...]

    July 22, 2026
  • Biotech & Pharma Business,Central Nervous System

    Alto Neuroscience raises $100M to expand Phase 3 treatment-resistant depression programme

    Alto Neuroscience has raised $100 million through an underwritten registered [...]

    July 15, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Research & Development

    Vandria reports Phase 1 data supporting Alzheimer’s development for VNA-318

    New Phase 1 data show Vandria’s VNA-318 reaches the human [...]

    July 13, 2026
  • Central Nervous System,Drug Discovery & Development,Research & Development

    CONNECTA highlights Fragile X data as Phase 2a trial advances

    CONNECTA Therapeutics will present preclinical data supporting its Phase 2a [...]

    July 3, 2026
  • Central Nervous System,Clinical & Regulatory,Pharmaceuticals and therapeutics

    Takeda’s oveporexton FDA decision tops GlobalData’s Q3 2026 biopharma catalysts

    GlobalData has identified Takeda’s oveporexton FDA decision as one of [...]

    June 25, 2026
Previous123Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • How AI is reshaping clinical trials: Saama on the next phase of regulated AI
    Categories: Clinical & Regulatory, Digital & Data, Drug Discovery & Development, Research & Development
  • MRI study suggests some prostate cancer biopsies could eventually be avoided
    Categories: Clinical & Regulatory, Medical devices, Research & Development, Therapeutic Areas
  • START and Allegheny Health Network to expand access to early-phase cancer trials
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top